We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Circassia Group Plc | LSE:CIR | London | Ordinary Share | GB00BJVD3B28 | ORD 0.08P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 34.00 | 33.10 | 34.90 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMCIR
RNS Number : 5783O
Circassia Pharmaceuticals Plc
18 May 2018
18 May 2018
Circassia Pharmaceuticals plc
Block Listing Application
Circassia Pharmaceuticals plc ("Circassia" or "the Company") today announces that an application (the "Application") has been made to the UK Listing Authority and the London Stock Exchange for a block listing of 400,000 ordinary shares of 0.08 pence each in the Company ("Ordinary Shares") to be admitted to trading on the Premium Segment of the London Stock Exchange.
The Application relates to Ordinary Shares to be issued from time to time in order to satisfy the potential exercise of share options granted under the 2015 Performance Share Plan Scheme.
It is expected that admission will become effective on 21 May 2018. When issued, the Ordinary Shares will rank pari passu with the existing ordinary shares of the Company.
As at today, there are 333,466,262 ordinary shares in issue with one voting right per share. The Company does not hold any shares in treasury. The Company will notify on a monthly basis when there are changes to the issued share capital of the Company, and these monthly figures may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
-Ends-
For further information, please contact:
Circassia Pharmaceuticals plc Julien Cotta, Company Tel: +44 (0) 1865 405 Secretary 560
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLRGGUMAAUPRUBR
(END) Dow Jones Newswires
May 18, 2018 05:57 ET (09:57 GMT)
1 Year Circassia Chart |
1 Month Circassia Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
